LivaNova is heading into a fresh quarter under genuine short-selling pressure, with short interest climbing more than 20% over the past month while the stock has dropped to its lowest close in nearly a year.
Short sellers have been stepping up systematically since mid-April. Short interest as a percentage of free float has risen from roughly 5.2% in late March to 6.4% now — a clear, steady build over six weeks rather than a single spike. The week-on-week increase of about 6% confirms the momentum is still running. Days to cover are 7.8, meaning it would take more than a week of average volume to close out current positions — not extreme, but meaningful enough to cause friction if the stock were to move against the shorts quickly. The ORTEX short score of 46.9 sits at a middling level, reflecting a stock where shorts are active but the setup is not yet at a squeeze-risk threshold.
The borrow market doesn't amplify that pressure. Cost to borrow has actually eased, dropping 21% over the past week to just 0.40% annualised — among the cheapest levels of the past two months. The borrow is freely available, meaning adding to short positions carries almost no carry cost right now. That low friction could be part of why shorts have been comfortable building: there is no financial penalty for staying in the trade. Availability remains well within normal ranges, and nothing in the lending market suggests imminent squeeze conditions.
Options positioning is broadly relaxed. The put/call ratio of 0.33 is slightly above its 20-day average of 0.30 but less than one standard deviation above it — hardly a defensive extreme. Over the past month the PCR has shifted meaningfully higher from the 0.15–0.20 range seen in early April, suggesting some incremental demand for downside protection has emerged, but the level itself remains call-heavy. The options market is not screaming concern; it's mildly more cautious than it was a month ago.
The Street tells a more constructive story than the short positioning might suggest. The consensus mean price target of roughly $80 implies nearly 38% upside from the current $57.59 close — a wide gap that reflects how far the stock has fallen relative to where analysts were pricing it after the last round of target raises. Barclays and Needham both lifted targets in late February, and multiple firms — including Mizuho, Baird, and Keybanc — carry positive ratings with targets in the $70–$81 range. The bull case centres on LivaNova's aura6000 device pipeline and its repositioned cardiopulmonary and neuromodulation businesses, with management guiding revenue toward $940–$955 million this year after $803 million in 2024. The bear case is more immediate: near-term revenue growth in the low single digits, margin pressure in both divisions, and the binary risk around FDA approval of the aura6000. EV/EBITDA has contracted 0.31 turns over the past month to 8.7x — cheap by medtech standards, but falling multiples in a declining stock are a difficult argument to make to a sceptical investor. The RSI of 33 is close to oversold territory, which alongside the valuation compression makes for a technically stretched picture.
Institutional holders are mixed. BlackRock's position as the largest holder grew modestly in the latest reported period. More notable is Millennium Management, which cut its stake by over 740,000 shares as of end-March — a significant reduction from one of the most active hedged holders on the register. American Century moved the other way, adding nearly 750,000 shares in the same window. Congress Asset Management appears to have initiated a new position of over 1.27 million shares. The insider picture from late March shows the CEO and CFO each received equity awards while simultaneously selling shares — consistent with tax-withholding sales tied to vesting rather than discretionary profit-taking.
The next confirmed earnings call is on June 10. The only recent post-earnings price reaction in the data — a modest -1.9% move on April 29 — is too limited to draw a reliable pattern. What makes the June print more consequential is the aura6000 regulatory timeline: the bull-case projections of $120 million in revenue by 2027 depend entirely on a positive FDA outcome, and any update on that front will likely dominate the market reaction. The short rebuild heading into that event is worth watching closely.
See the live data behind this article on ORTEX.
Open LIVN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
